Skip to main content
. Author manuscript; available in PMC: 2015 Oct 28.
Published in final edited form as: Arthritis Rheumatol. 2015 Jan;67(1):28–38. doi: 10.1002/art.38904

Figure 1.

Figure 1

Serum levels of matrix metalloproteinase 7 (MMP-7) and interferon-γ–inducible protein 10 (IP-10) in rheumatoid arthritis (RA) patients in the Chinese identification cohort (A) and the US replication cohort (B) without interstitial lung disease (ILD) or with different stages of ILD. Dot plots depict levels (measured by standard solid-phase enzyme-linked immunosorbent assay) of MMP-7 or IP-10 in individual serum samples from RA patients without ILD (interstitial lung abnormality [ILA] score 0), indeterminate ILD (ILA score 1), mild ILD (ILA score 2), or advanced ILD (ILA score 3). Samples from patients with ILA scores of 2 or 3 were further stratified into groups of subclinical ILD versus clinically evident/symptomatic ILD (based on the presence of cough and/or dyspnea). Each symbol represents an individual patient; horizontal lines show the mean. P values were determined by Mann-Whitney U test.